Mads Krogsgaard Thomsen, the Chief Science Officer for Novo Nordisk A/S, recently claimed that their experimental “insulin Degludec” is likely to acquire Sanofi’s Lantus, most probably within next decade.

Degludec assisted in limiting blood-sugar levels for diabetic patients. In addition, Lantus, one of the world’s best selling insulin medications, is highly imperative in reducing diabetic concerns.

According to a latest study reported yesterday at a conference in Lisbon dubbed ‘Conference for the European Association for the Study of Diabetes’, Novo Nordisk expressed its intent regarding Degludec being the first ever insulin drug approved for exercise throughout the day.

This will certainly enhance its possibilities leapfrog Lantus, which as per Sanofi, is excessively employed by more than 7 million individuals.

Diabetes is a pathetic situation which sparks various social, mental and physical concerns for the victim. According to the latest reports revealed by the International Diabetes Federation, the dreadful condition of diabetes has engulfed in excess of 366 million people, throughout the world.

The condition is inspired by a deficiency of insulin which is required to create energy from blood sugar. An elevated sugar levels can cause kidney rupture, heart strokes and other similar problems, blindness, and even death.

The study revealed that diabetics using Degludec once a day (any time during the day) better managed their situation, when compared to those using Sanofi’s Lantus at a specific time of the day.